Published Online
on September 14, 2009

A more recent version of this article appeared on September 29, 2009

This Article Full Text (PDF) All Versions of this Article: 120/13/1169    most recent CIRCULATIONAHA.109.893438v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Ezekowitz, M. D. Articles by Fulton, B. PubMed PubMed Citation Articles by Ezekowitz, M. D. Articles by Fulton, B. Related Collections Arrhythmias, clinical electrophysiology, drugs Anticoagulants Antiplatelets Neuroprotectors Other Stroke Treatment - Medical Related Article

Submitted on ,
Accepted on ,

Reducing Stroke Rates in Patients With Atrial Fibrillation. How Low Can We Go?

Michael D. Ezekowitz MBChB, DPhil^*, Meghashyam J. Koti MD, and Brian Fulton BS

From the Lankenau Institute for Medical Research, Wynnewood, Pa (M.D.E., M.J.K., B.F.).

^* To whom correspondence should be addressed. E-mail: EzekowitzM{at}mlhs.org.

Key words: Editorials • antiarrhythmia agents • anticoagulants • arrhythmia • fibrillation • stroke

Related Article:

Analysis of Stroke in ATHENA: A Placebo-Controlled, Double-Blind, Parallel-Arm Trial to Assess the Efficacy of Dronedarone 400 mg BID for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter

Stuart J. Connolly, Harry J.G.M. Crijns, Christian Torp-Pedersen, Martin van Eickels, Christophe Gaudin, Richard L. Page, Stefan H. Hohnloser for the ATHENA Investigators
Circulation 2009 120: 1174-1180. [Abstract] [Full Text]